{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:17:04Z","timestamp":1787023024710,"version":"build-2736575974"},"reference-count":135,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1586\/14737140.2014.941815","type":"journal-article","created":{"date-parts":[[2014,7,28]],"date-time":"2014-07-28T06:50:32Z","timestamp":1406530232000},"page":"983-999","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["The use of sunitinib in renal cell carcinoma: where are we now?"],"prefix":"10.1586","volume":"14","author":[{"given":"Anna M","family":"Czarnecka","sequence":"first","affiliation":[{"name":"Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Szczylik","sequence":"additional","affiliation":[{"name":"Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Rini","sequence":"additional","affiliation":[{"name":"Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,7,28]]},"reference":[{"issue":"4","key":"e_1_3_4_5_1","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal A","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49","journal-title":"CA"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2341031733"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574362409666140206222431"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609193351207"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.2302\/kjm.58.1"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.13.258"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357901003631080"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq554"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09829.x"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0443"},{"issue":"1","key":"e_1_3_4_15_1","first-page":"75","article-title":"Gene expression profiles correlate with the morphology and metastasis characteristics of renal cell carcinoma cells","volume":"13","author":"Ami Y","year":"2005","unstructured":"Ami Y, Shimazui T, Akaza H, et al. Gene expression profiles correlate with the morphology and metastasis characteristics of renal cell carcinoma cells. Oncol Rep 2005;13(1):75-80","journal-title":"Oncol Rep"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574362409666140206222251"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2013.10.001"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574362409666140206223014"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe068263"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.010"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61613-9"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.058"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.06.001"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.09.001"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.33"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00738.x"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/11590230-000000000-00000"},{"issue":"5","key":"e_1_3_4_30_1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1464-410X.2010.09957.x","article-title":"Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma","volume":"108","author":"Benedict A","year":"2011","unstructured":"Benedict A, Figlin RA, Sandstrom P, et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int 2011;108(5):665-72","journal-title":"BJU Int"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.3602"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26426"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0204183"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0333"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3722"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4323"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.09618"},{"issue":"1","key":"e_1_3_4_38_1","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel DB","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 2003;9(1):327-37","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-004-3149-y"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05616.x"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.186"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.21.2516"},{"issue":"10","key":"e_1_3_4_43_1","first-page":"1011","article-title":"Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with \"standard of care\" therapeutic agents for the treatment of breast cancer","volume":"2","author":"Abrams TJ","year":"2003","unstructured":"Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with \"standard of care\" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2(10):1011-21","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.2574"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-32"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s32341"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1893"},{"issue":"15","key":"e_1_3_4_48_1","first-page":"5465","article-title":"An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients","volume":"9","author":"O\u2019Farrell AM","year":"2003","unstructured":"O\u2019Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003;9(15):5465-76","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1846"},{"issue":"12","key":"e_1_3_4_50_1","first-page":"1329","article-title":"Su-11248 Sugen","volume":"5","author":"Sakamoto KM","year":"2004","unstructured":"Sakamoto KM. Su-11248 Sugen. Curr Opin Investig Drugs 2004;5(12):1329-39","journal-title":"Curr Opin Investig Drugs"},{"issue":"14","key":"e_1_3_4_51_1","article-title":"SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial","volume":"22","author":"Motzer RJ","year":"2004","unstructured":"Motzer RJ, Rini BI, Michaelson MD, et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial. Proc Am Soc Clin Oncol 2004;22(14):suppl 4500","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.2194"},{"key":"e_1_3_4_53_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00054886"},{"key":"e_1_3_4_54_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00077974"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds227"},{"key":"e_1_3_4_56_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00903175"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.15_suppl.4504"},{"key":"e_1_3_4_58_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00083889"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.59"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303989"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5476"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq206"},{"key":"e_1_3_4_64_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01108445"},{"key":"e_1_3_4_65_1","doi-asserted-by":"crossref","first-page":"Abstract TPS459","DOI":"10.1200\/jco.2013.31.15_suppl.tps4590","article-title":"ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma","volume":"31","author":"Armstrong AJ","year":"2013","unstructured":"Armstrong AJ, Halabi S, Eisen T, et al. ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma. J Clin Oncol 2013;31(Suppl):Abstract TPS4590","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_66_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00979966"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr586"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.3223"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.123"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25452"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70162-7"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7410"},{"key":"e_1_3_4_73_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00130897"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-009-0664-7"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2013.05.002"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287212466128"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1068"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2844"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.01.003"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s4052"},{"key":"e_1_3_4_81_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00720941"},{"key":"e_1_3_4_82_1","doi-asserted-by":"crossref","first-page":"Abstract CRA450","DOI":"10.1200\/jco.2012.30.18_suppl.cra4502","article-title":"Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)\u2014PISCES study, NCT 01064310","volume":"30","author":"Escudier BJ","year":"2012","unstructured":"Escudier BJ, Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)\u2014PISCES study, NCT 01064310. J Clin Oncol 2012;30(Suppl):Abstract CRA4502","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_83_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01064310"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.647406"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.01.002"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61865-0"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2012.03204.x"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2012.03033.x"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.149690"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0120"},{"issue":"2","key":"e_1_3_4_91_1","first-page":"S41","article-title":"Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects","volume":"1","author":"Kollmannsberger C","year":"2007","unstructured":"Kollmannsberger C, Soulieres D, Wong R, et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007;1(2 Suppl):S41-54","journal-title":"Can Urol Assoc J"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1159\/000329933"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr128"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23460"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-011-0225-8"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0263"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk008"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0125"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03253.x"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.0308"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25422"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2010.07.015"},{"issue":"2","key":"e_1_3_4_103_1","first-page":"120","article-title":"Modifying sunitinib schedule in advanced kidney cancer patients: reflections from the results of the renal EFFECT trial","volume":"1","author":"Porta C","year":"2012","unstructured":"Porta C, Ganini C, Paglino C. Modifying sunitinib schedule in advanced kidney cancer patients: reflections from the results of the renal EFFECT trial. Transl Androl Urol 2012;1(2):120-2","journal-title":"Transl Androl Urol"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604456"},{"key":"e_1_3_4_105_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01499121"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr511"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-S2-32"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0498-4"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1170-y"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.08.090"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.6_suppl.406"},{"issue":"4","key":"e_1_3_4_112_1","first-page":"202","article-title":"Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma","volume":"1","author":"Nozawa M","year":"2012","unstructured":"Nozawa M, Uemura H. Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma. Transl Androl Urol 2012;1(4):202-3","journal-title":"Transl Androl Urol"},{"key":"e_1_3_4_113_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00267748"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.4133"},{"key":"e_1_3_4_115_1","article-title":"Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer","author":"Czarnecka AM","year":"2014","unstructured":"Czarnecka AM, Oborska S, Rzepecki P, Szczylik C. Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. Future Oncol 2014. [Epub ahead of print]","journal-title":"Future Oncol"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1351"},{"issue":"1","key":"e_1_3_4_117_1","first-page":"90","article-title":"Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - apoptosis-regulating factors","volume":"16","author":"Mlot B","year":"2012","unstructured":"Mlot B, Szczylik C, Rzepecki P. Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - apoptosis-regulating factors. Contemp Oncol (Pozn) 2012;16(1):90-3","journal-title":"Contemp Oncol (Pozn)"},{"issue":"3","key":"e_1_3_4_118_1","first-page":"250","article-title":"Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - hypoxia-induced factors","volume":"16","author":"Mlot B","year":"2012","unstructured":"Mlot B, Szczylik C, Rzepecki P. Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - hypoxia-induced factors. Contemp Oncol (Pozn) 2012;16(3):250-3","journal-title":"Contemp Oncol (Pozn)"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.4_suppl.393"},{"key":"e_1_3_4_120_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01219751"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9491-6"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.06.043"},{"key":"e_1_3_4_123_1","unstructured":"ClinicalTrial.gov. Available from: http:\/\/clinicaltrials.gov\/show\/NCT00465179?displayxml=true"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-008-9146-z"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.516"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212457968"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e32832e4681"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.4166\/kjg.2013.61.6.347"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-011-0318-z"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2011.03.021"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds145"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09290.x"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23711"},{"issue":"3","key":"e_1_3_4_134_1","first-page":"1","article-title":"Development of CML in the course of ccRCC treatment with tyrosine kinase inhibitors \u2013 clinical report with molecular model","volume":"112","author":"Czarnecka AM","year":"2013","unstructured":"Czarnecka AM, Oborska S, Rzepecki P, Szczylik C. Development of CML in the course of ccRCC treatment with tyrosine kinase inhibitors \u2013 clinical report with molecular model. BJU Int 2013;112(Suppl 3):1-17","journal-title":"BJU Int"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn625"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1291-3"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp666"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181eefe8b"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60903-9"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14737140.2014.941815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:34:55Z","timestamp":1770906895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14737140.2014.941815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,28]]},"references-count":135,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1586\/14737140.2014.941815"],"URL":"https:\/\/doi.org\/10.1586\/14737140.2014.941815","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-07-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}